Antiverse collaborates with one of the top 20 pharmaceutical companies
Project demonstrates potential of Antiverse’s platform to reduce time and cost associated with antibody drug discovery
Antiverse, a biotech company developing an antibody-based drug discovery informatics platform, announced a partnership with one of the top 20 pharmaceutical companies with core competencies in healthcare life science areas. health and nutrition. The collaboration was successful in identifying candidate antibodies for a target of interest, with greater diversity (2.3x) and greater precision compared to alternative bioinformatics pipeline selection methods.
Using Antiverse’s proprietary AI-augmented drug discovery platform, 248 sequences were identified, of which more than 230 were antibody binders. Five of these candidate antibodies were found to be cross-reactive.
Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to provide various candidate antibodies for a given target. The technology is being developed to enable drug development for ‘hard’ targets associated with cancer, heart and lung disease. The platform will overcome limitations commonly associated with traditional screening, including overcoming amplification bias that leads to loss of diversity and selection bias that leads to loss of unique antibodies.
Murat Tunaboylu, CEO of Antiverse, said, “We are delighted to be collaborating with one of the top 20 pharmaceutical companies on this discovery project. Our AI-powered antibody drug discovery platform has successfully identified more binders with better diversity for high-throughput colony selection and state-of-the-art bioinformatics pipeline selection. Researchers can find more diverse antibodies by unlocking the full potential of their library/discovery process with our AI-augmented discovery platform and through our fee-for-service offering, we hope to partner with others biotech and pharmaceutical companies on projects to identify further challenges. targets. »
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>